Tagged with cell

Global On 7 October 2020, the 2020 Nobel Prize in Chemistry was jointly awarded to Emmanuelle Charpentier and Jennifer A. Doudna “for the development of a method for genome editing.” They are the sixth and seventh female chemistry laureates in the history of the prize.   Emmanuelle Charpentier was born in…

Europe Professor Nicolaus Kröger, president of the European Society for Blood and Marrow Transplantation (EBMT) introduces the multi-stakeholder GoCART Coalition and the impact that it stands to have on the cell and gene therapy field in Europe.   It was critical to build a coalition that is win-win for everyone Nicolaus,…

InFocus BACK TO HOME     Cell & Gene Therapy   BACK TO HOME Stefan Hendriks Global Head, Cell & Gene, Novartis Oncology Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he…

Switzerland Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the strain on resources that genomic medicine can contribute to. Professor Szucs also evaluates the sustainability of personalized medicine and China’s rapid progress in the field.  …

Europe The EMA’s Head of Advanced Therapies Dr Ana Hidalgo-Simon outlines Europe’s evolving regulatory framework for regenerative medicines, how it differs from those in the USA and Asia, ethical and pricing challenges, and why global regulatory harmonization and collaboration is crucial.   For advanced therapies, market approval is not the end…

China While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in 2003! Gendicine® was a gene therapy for the treatment of haemophilia B. While China mostly lost the advantage of that…

Opinion Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the myriad benefits of collaborative, as opposed to command, leadership, the impact of company and team culture on the innovation journey, and why we must not confuse collaboration with…

China Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company. The company’s CEO spoke to PharmaBoardroom about how Edigene’s technology platforms differ from those of other firms, and why the…

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive major medical advances and new treatments.   Here’s what we know today and what we’ll need to do tomorrow to benefit from the promises…

USA Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under development, and why an open and collaborative approach among US healthcare stakeholders is needed if the significant legal and practical barriers are to be overcome.   The…

Norway Photo: Sofia Linden / Oslo Cancer Cluster Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer…

Japan Dr Ken-ichiro Hata, representative director and chairperson of Japan’s Forum for Innovative Regenerative Medicine (FIRM) outlines the organisation’s mandate, how Japan has been able to cultivate one of the world’s most mature regenerative medicine ecosystems, and highlights key challenges including regulatory misalignment across Asia and the need for better manufacturing…